Professor, Internal Medicine, University of Nebraska Medical Center College of Medicine
Hematology
Dr. Jean L. Grem, MD
|
|
Give Review
Doctor Jean L. Grem, MD works in the field of Hematology. He went to medical school at Jefferson Medical College. He has 3 awards "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification" and "America's Top Doctors for Cancer". Doctor Jean L. Grem, MD is also a published physician. He has 26 paper published. The most recent paper is: A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid Tumors.
- Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in pancreatic Cancer patients.
- Sequencing of treatment in advanced unresectable colorectal Cancer.
- Localized Colon Cancer, Version 3.2013.
- Metastatic Colon Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines.
- Colon Cancer.
- Fatigue and other variables during adjuvant chemotherapy for colon and rectal Cancer.
- National Institutes of Health consensus development conference statement: management of hepatitis B.
- Oxaliplatin pharmacokinetics and pharmacodynamics in adult Cancer patients with impaired renal function.
- Screening for dihydropyrimidine dehydrogenase deficiency.
- A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult p...
- Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid Tumors.
- Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal Cancer.
- Mature results of adjuvant colon Cancer trials from the fluorouracil-only era.
- Measurement of the antiCancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry.
- Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national Cancer institute organ dysfunction working group.
- Hypersensitivity and idiosyncratic reactions to oxaliplatin.
- Measurement of the anti-Cancer agent gemcitabine in human plasma by high-performance liquid chromatography.
- Liquid chromatography-mass spectrometry method for the analysis of the anti-Cancer agent capecitabine and its nucleoside metabolites in human plasma.
- Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric Cancer.
- A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult Cancer patients.
- Impact of two weekly schedules of Oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
- Acute oxaliplatin-induced peripheral nerve hyperexcitability.
- Erratum to "NCCAM/NCI Phase 1 Study of Mistletoe ExTract and Gemcitabine in Patients with Advanced Solid Tumors"
- NCCAM/NCI Phase 1 Study of Mistletoe ExTract and Gemcitabine in Patients with Advanced Solid Tumors.
Schools
Jefferson Medical College Of Thomas Jefferson University Thomas Jefferson University
University Ia Hosps Clins
University Wisc Clin Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Accord
- Cigna
- Commercial Insurance Company
- Coventry Health Care
- Coventry Health Care of Nebraska PPO
- First Health (Coventry Health Care) PPO
- Health Alliance
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Principal Life
- Thrivent Financial
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
- Universal American
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
Education
-
University of Wisconsin -
University of Iowa Hospitals and Clinics -
Jefferson Medical College
Drug Facts
| NPI NUMBER | 1609824424 | |
| NPPES Provider LastName | GREM | |
| NPPES Provider FirstName | JEAN | |
| NPPES Provider ZIPCode | 681988102 | |
| NPPES Provider State | NE | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1159.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 150.0 | |
| Percent Opioid Claims | 12.94 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1609824424 |
| Last Name Of The Provider | GREM |
| First Name Of The Provider | JEAN |
| View All |
Similar Doctors
|
|
Kari L. Cunningham, APRN |
|
|
Danielle L. Geiger, APRN |
|
|
Margaret J. Rebensdorf, APRN
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Lyudmyla Berim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James O. Armitage, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Maureen G. Conlan, MD |
|
|
Dr. Herbert A. Hartman Jr., MD |
|
|
Dr. Qinglong Hu, MD |
|
|
Dr. Sadiq U. Zaman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David G. Crockett, MD |
|
|
Dr. Kai Fu, MD
This Doctor is OpenDoctor Recommended.
|